5.3.3. vaporisation prostate. 5.3.3.1. bipolar transurethral vaporisation prostate mechanism action: mechanism action: bipolar transurethral vaporisation prostate (b-tuvp) utilises bipolar electrode high-frequency generator create plasma field (thin layer highly ionised particles) vaporise prostatic tissue . bipolar transurethral vaporisation prostate displays thinner (< 2 mm) coagulation zones , compared monopolar tuvp (up 10 mm) , potentially resulting fewer irritative side-effects sui . efficacy: bipolar-tuvp compared turp thirteen rcts, including total 1,244 men prostate size < 80 ml [334,465-476]. early rcts evaluated pk b-tuvp system [465-469]; however, last decade, “plasma” b-tuvp system “mushroom- button-like” electrode (olympus, medical) evaluated [334,470-476]. results pooled three meta-analyses , narrative synthesis produced two srs . follow-up rcts twelve months [465-468,470-472,474,476] longest 36 months small rct (n = 40) eighteen months subsequent rct (n = 340); evaluating pk plasma b-tuvp , respectively. pooled results meta-analyses concluded significant differences exist short-term efficacy (ipss, qol score, qmax pvr) pk b-tuvp turp confirmed separate sr seven rcts . however, promising initial efficacy profile former may compromised inferior clinical outcomes (ipss qmax) mid-term. higher quality rcts longer follow-up necessary draw definite conclusions mid long-term outcomes . tolerability safety: early pooled results concluded statistically significant differences exist intra-operative short-term complications pk b-tuvp turp, peri-operative complications significantly fewer b-tuvp . however, results statistical analysis comparing pooled specific complication rates directly reported meta-analysis . mid-term complications (urethral stricture, ed, retrograde ejaculation) similar , larger rcts longer follow-up necessary draw definite conclusions . sr seven rcts comparing pk plasma b-tuvp turp concluded rcts shorter catheterisation (42.5 vs. 77.5 hours) hospitalisation times (3.1 vs. 4.4 days) b-tuvp , another sr concluded heterogeneity rcts, methodological limitations permit firm conclusions . meta-analysis reported b-tuvp shorter similar catheterisation time compared m-turp b-turp, respectively; significantly fewer clot retentions/blood transfusions compared m-turp b-turp; difference complication rates compared either turp technique . meta-analysis six rcts specifically evaluating plasma b-tuvp vs. turp, concluded significant differences exist techniques overall complication transfusion rates . however, statistically significant difference detected major complication rates (clavien 3, 4), including urethral stricture, severe bleeding necessitating re-operation ui, duration catheterisation, favouring plasma b-tuvp. practical considerations: bipolar-tuvp pk tuvp similar short-term efficacy turp, favourable short-term safety profile. however, heterogeneity rcts, non-standardised techniques methodological limitations permit firm conclusions, multicentre, long-term rcts needed. summary evidencelebipolar-tuvp turp similar short-term efficacy.1aplasmakinetic b-tuvp favourable peri-operative profile, similar mid-term safety inferior mid-term efficacy compared turp.1aplasma b-tuvp lower short-term major morbidity rate compared turp.1a recommendationstrength ratingoffer bipolar transurethral vaporisation prostate alternative transurethral resection prostate surgically treat moderate-to-severe luts men prostate volume 30-80 ml.weak 5.3.3.2. 532 nm (‘greenlight’) laser vaporisation prostate mechanism action: ktp lbo lasers described section 5.3.2.6.2. efficacy: meta-analyses rcts comparing photoselective vaporisation prostate (pvp) using 80-w 120-w lasers turp reported difference qmax ipss 80-w 120-w pvp turp . another meta-analysis four rcts including 559 patients, 120-w laser, demonstrated significant difference functional symptomatic parameters 24-month follow-up compared turp . meta-analysis two rcts reported similar efficacy 120-w pvp, compared m-turp 36-months follow-up . available rct 180-w laser reported non-inferiority turp terms ipss, qmax, pvr, prostate volume reduction, psa decrease qol questionnaires. efficacy outcomes similar turp stable results 24-months follow-up . one rct comparing holep pvp, patients prostates > 60 ml, showed comparable symptom improvement, significantly higher flow rates lower pvr volume holep short-term follow-up; addition, pvp showed 22% conversion rate turp . one rct compared b-tuvp pvp 180-w xps laser. comparable improvement ipss qmax reported 24-months follow-up . tolerability safety: meta-analysis rcts comparing 80-w 120-w lasers turp showed shorter catheterisation time (mean difference 32 hours) length hospital stay (mean difference 1.85 days) pvp . blood transfusions clot retention less pvp. difference noted post-operative urinary retention, uti, meatal stenosis, urethral stricture, bladder neck stenosis . meta-analysis including trials 120-w laser likewise reported lower transfusion rates, catheterisation time duration hospital stay compared turp. re-operation rates operation time favour turp. significant differences demonstrated treatment urethral stricture, bnc, incidence incontinence uti . meta-analysis confirmed pvp superior m-turp/b-turp regard catheterisation m-turp b-turp regard transfusion rate clot retention . rct comparing 120-w hps laser turp, follow-up 36-months, re-operation rate significantly higher pvp (11% vs. 1.8%) . 180-w greenlight laser prostatectomy non-inferior turp terms peri-operative complications. re-operation free survival 24-month follow-up comparable turp-arm 180-w xps laser-arm . retrospective feasibility study 537 patients median follow-up 31 months, 517 treated outpatient basis, showed outpatient pvp 180-w xps laser performed safely low re-admission complication rate . one retrospective long-term follow study 21,869 patients treated twenty centres finland compared short-term long-term morbidity patients undergoing monopolar bipolar turp three generations pvp . re-operations bleeding less frequent pvp. cumulative incidence re-operation higher pvp (23.5%) turp long-term follow-up (17.8%) . based mostly case series, 80-,120- 180-w greenlight laser appears safe high-risk patients undergoing anticoagulation treatment [489-492]; however, patients anticoagulation therapy either excluded represented small sample currently available rcts. one study, anticoagulated patients significantly higher rates bladder irrigation (17.2%) compared taking anticoagulants (5.4%) . contrast, another retrospective study focusing 180-w lbo laser find significant differences patients receiving receiving anticoagulants . retrospective study mixed cohort patients, treated 80-w ktp pvp 120-w lbo hps, revealed delayed gross haematuria common patients (33.8%) average follow-up 33 months . retrospective review database patients undergoing 180-w pvp, without interruption anticoagulation therapy, 30.5% rate peri-operative adverse events significant occurrence high grade clavien dindo events . safety patients urinary retention, impaired detrusor contractility, elderly patients prostates > 80 ml shown various prospective short-term non-randomised trials. retrospective study 1,077 patients median eighteen months follow-up, compared functional results safety profile pvp patients younger older 75 years age. authors find differences terms complications older patients, 0.6% clavien iii overall complications rate 29.6%. data functional outcomes older group patients, showed amelioration parameters baseline, 111.7% improvement peak flow 69.5% ipss reduction without statistical differences counterparts twelve months. however similarity results disappears extending study period median eighteen months, underlying fact younger patients maintain improvement older patients, nevertheless maintain relevant improvement compared baseline . rct including prostates > 100 ml reported; therefore, comparison retreatment rates prostate volumes different sizes possible [497-499]. meta-analysis five rcts comparing collectively three “greenlight” lasers turp detected difference retrograde ejaculation rates . additional studies also reported difference op/turp greenlight pvp erectile function . however, iief-5 scores significantly decreased six-, twelve-, 24- months patients pre-operative iief-5 greater nineteen . significant difference respect peri- post-operative complications reported rct comparing b-tuvp pvp 180-w xps laser. redo turp recurrent adenoma required 9.8% (b-tuvp) 1.7% (pvp) patients 24-months follow-up, respectively . practical considerations: 180-w xps represents current standard generators pvp; however, number quality supporting publications low, especially large glands (> 100 ml), long-term follow-up. summary evidencelelaser vaporisation prostate using 80-w ktp 120-w lbo laser (pvp) demonstrated higher intra-operative safety regard haemostatic properties compared turp. peri-operative parameters catheterisation time hospital stay favour pvp, whereas operation time risk re-operation favour turp. short-term results 80-w ktp laser mid-term results 120-w lbo laser comparable turp.1alaser vaporisation prostate using 180-w lbo laser (pvp) demonstrated higher intra-operative safety regard haemostatic properties compared turp. peri-operative parameters catheterisation time hospital stay favour pvp, whereas operation time favour turp. short- mid-term results comparable turp.1blaser vaporisation prostate using 80-w ktp 120-w lbo lasers seems safe treatment patients receiving antiplatelet anticoagulant therapy.2laser vaporisation prostate using 180-w lbo laser seems safe treatment patients receiving antiplatelet anticoagulant therapy; however, level evidence available low.3 recommendationsstrength ratingoffer 80-w 532-nm potassium-titanyl-phosphate (ktp) laser vaporisation prostate men moderate-to-severe luts prostate volume 30-80 ml alternative transurethral resection prostate (turp).strongoffer 120-w 532-nm lithium borat (lbo) laser vaporisation prostate men moderate-to-severe luts prostate volume 30-80 ml alternative turp.strongoffer 180-w 532-nm lbo laser vaporisation prostate men moderate-to-severe luts prostate volume 30-80 ml alternative turp.strongoffer laser vaporisation prostate using 80-w ktp, 120- 180-w lbo lasers treatment patients receiving antiplatelet anticoagulant therapy prostate volume < 80 ml.weak 5.3.3.3. vaporisation techniques investigation 5.3.3.3.1. diode laser vaporisation prostate mechanism action: diode lasers wavelength 980 nm marketed prostate vaporisation; however, evaluated clinical trials . efficacy: two rcts 120-w 980 nm diode laser vaporisation vs. m-turp available . first rct 24-month follow-up reported similar efficacy (ipss, qmax pvr) one six months. however, twelve- 24-months improvements ipss qmax significantly favour turp, repeat turp frequent diode laser group . second rct reported equivalent results interventions three-month follow-up . tolerability safety: meta-analysis comparing diode laser vaporisation vs. m-turp reported shorter catheterisation time lower transfusion rates diode laser vaporisation . rct reflecting peri-operative post-operative complications significant differences demonstrated clot retention, aur catheter removal, uui uti . moreover, late complications significant differences could demonstrated re-operation rate, urethral stricture, bladder neck sclerosis, de novo sexual dysfunction mean time dysuria . published studies 980 nm diode laser vaporisation indicate high haemostatic potential, although anticoagulants platelet aggregation inhibitors taken 24% 52% patients, respectively . number studies, high rate post-operative dysuria reported [503,505-507]. early publications diode vaporisation reported high re-operation rates (8-33%) persisting sui (9.1%) [503,505-507]. practical considerations: diode laser vaporisation leads similar improvements clinical symptomatic parameters short-term follow-up provides good haemostatic properties. based limited number mainly low quality rcts, controversial data retreatment rate, results diode laser vaporisation evaluated higher quality rcts. summary evidencelelaser vaporisation prostate using 120-w 980 nm diode laser demonstrated high intra-operative safety regard haemostatic properties compared turp. peri-operative parameters like catheterisation time hospital stay favour diode lasers. evidence limited number quality available studies.1bin number studies, post-operative complications severe storage symptoms persisting incontinence, occurred laser vaporisation prostate using 120-w 980 nm diode laser.3laser vaporisation using 120-w 980 nm diode laser seems safe regard haemostasis patients receiving anticoagulant therapy.3